Literature DB >> 7584138

Resident bone marrow macrophages produce type 1 interferons that can selectively inhibit interleukin-7-driven growth of B lineage cells.

J Wang1, Q Lin, H Langston, M D Cooper.   

Abstract

Type 1 interferons alpha and beta are found to be potent inhibitors of IL-7-induced growth of early B lineage cells, while having no effect on cell growth induced by IL-2, IL-3, IL-4, or autogenous factors. The combination of IL-7 and interferons alpha/beta induces bcl-2 down-regulation and cell death by apoptosis. These conclusions were derived initially from experiments employing exogenous cytokines, but functional type 1 interferons are also shown to be produced by resident bone marrow macrophages. As physiological modulators of IL-7-driven proliferation and cell survival, interferons alpha/beta may cooperate with other homeostatic factors to maintain the balanced production of normal B lineage cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7584138     DOI: 10.1016/1074-7613(95)90176-0

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  23 in total

1.  Type I interferons activate apoptosis in a Jurkat cell variant by caspase-dependent and independent mechanisms.

Authors:  Ana M Gamero; Ramesh Potla; Shuji Sakamoto; Darren P Baker; Robert Abraham; Andrew C Larner
Journal:  Cell Signal       Date:  2005-12-06       Impact factor: 4.315

2.  Antiviral instruction of bone marrow leukocytes during respiratory viral infections.

Authors:  Tamar Hermesh; Bruno Moltedo; Thomas M Moran; Carolina B López
Journal:  Cell Host Microbe       Date:  2010-05-20       Impact factor: 21.023

Review 3.  Cell circuits and niches controlling B cell development.

Authors:  Sandra Zehentmeier; João P Pereira
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

4.  Interferons alpha/beta inhibit IL-7-induced proliferation of CD4- CD8- CD3- CD44+ CD25+ thymocytes, but do not inhibit that of CD4- CD8- CD3- CD44- CD25- thymocytes.

Authors:  D M Su; J Wang; Q Lin; M D Cooper; T Watanabe
Journal:  Immunology       Date:  1997-04       Impact factor: 7.397

5.  E2A promotes the survival of precursor and mature B lymphocytes.

Authors:  Adam S Lazorchak; Jason Wojciechowski; Meifang Dai; Yuan Zhuang
Journal:  J Immunol       Date:  2006-08-15       Impact factor: 5.422

6.  Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model.

Authors:  Jadwiga Jablonska; Sara Leschner; Kathrin Westphal; Stefan Lienenklaus; Siegfried Weiss
Journal:  J Clin Invest       Date:  2010-03-08       Impact factor: 14.808

7.  Tyk2 tyrosine kinase expression is required for the maintenance of mitochondrial respiration in primary pro-B lymphocytes.

Authors:  Ramesh Potla; Thomas Koeck; Joanna Wegrzyn; Srujana Cherukuri; Kazuya Shimoda; Darren P Baker; Janice Wolfman; Sarah M Planchon; Christine Esposito; Brian Hoit; Jozef Dulak; Alan Wolfman; Dennis Stuehr; Andrew C Larner
Journal:  Mol Cell Biol       Date:  2006-09-18       Impact factor: 4.272

8.  Toll-like receptor 4-mediated signaling regulates IL-7-driven proliferation and differentiation of B-cell precursors.

Authors:  Qian Li; Dongmei Han; Wei Wang; Xiaoqing Liu; Xiuyuan Sun; Jun Zhang; Rong Li; Yu Zhang
Journal:  Cell Mol Immunol       Date:  2013-12-09       Impact factor: 11.530

9.  CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7.

Authors:  Marta Catalfamo; Christopher Wilhelm; Lueng Tcheung; Michael Proschan; Travis Friesen; Jung-Hyun Park; Joseph Adelsberger; Michael Baseler; Frank Maldarelli; Richard Davey; Gregg Roby; Catherine Rehm; Clifford Lane
Journal:  J Immunol       Date:  2011-01-21       Impact factor: 5.422

Review 10.  Does cytokine signaling link sphingolipid metabolism to host defense and immunity against virus infections?

Authors:  Young-Jin Seo; Stephen Alexander; Bumsuk Hahm
Journal:  Cytokine Growth Factor Rev       Date:  2011-01-19       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.